What is EverImmune?
Founded in 2016 and headquartered in Villejuif, France, EverImmune is at the forefront of microbiota-based oncology research. The company leverages the intricate relationship between the gut microbiome and cancer to develop novel therapeutic strategies. By targeting the body's own microbial ecosystem, EverImmune aims to create more effective and potentially less toxic cancer treatments, positioning itself as a key player in the evolving field of precision medicine and immunotherapy.
How much funding has EverImmune raised?
EverImmune has raised a total of $9.4M across 2 funding rounds:
Series A
$6M
Private Equity
$3.4M
Series A (2021): $6M, investors not publicly disclosed
Private Equity (2023): $3.4M led by Bpifrance
Key Investors in EverImmune
Bpifrance
Bpifrance is a French public investment bank that finances companies at every stage of their development, supporting innovation, international expansion, and export activities. They provide credit, guarantees, and equity, along with consulting and acceleration programs for businesses.
What's next for EverImmune?
With the recent influx of capital, EverImmune is poised to accelerate its research and development pipeline, potentially moving promising candidates closer to clinical trials. The strategic nature of the latest investment suggests a strong belief in the company's technology and market potential. Future endeavors will likely focus on expanding its scientific team, forging strategic partnerships, and advancing its lead programs through rigorous preclinical and clinical validation, aiming to solidify its position as a leader in microbiota oncology.
See full EverImmune company page
